Seqirus is the 2nd largest influenza vaccine company in the world with a rich heritage in influenza dating back to the Spanish flu pandemic (through its parent company CSL). With manufacturing plants in the US, UK, Germany and Australia, it is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus recently announced innovations in cell-based influenza vaccine development at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs. This accelerated development of cell-based technology quadruples influenza vaccine output in just two years, strengthening US preparedness against pandemic threats. The company is also leveraging its global manufacturing network to supply pandemic stockpiles and other preparedness services to governments around the world.
Ethan Settembre is the Vice President of Research at Seqirus.
Please register by clicking on the flyer below: